open access

Vol 11, No 1 (2017)
Case report
Published online: 2017-09-19
Get Citation

Neuropathic pain after chemotherapy treated with tapentadol — a case report

Anna Przeklasa-Muszyńska, Magdalena Kocot-Kępska, Jan Dobrogowski
Medycyna Paliatywna w Praktyce 2017;11(1):36-40.

open access

Vol 11, No 1 (2017)
Case report
Published online: 2017-09-19

Abstract

Neuropathic pain is a pain caused by damage or disease affecting the somatosensory nervous system (peripheral or central). There may be various origins of NP, such as infection, trauma, metabolic disorders, chemotherapy, surgery and/or neural compression. Patients usually report a continuous burning pain, which may be accompanied by paroxysms of lancinating or electrical pain — spontaneous or secondary to small stimuli. Pain may occur as response to a painful stimulus (hyperalgesia), or in response to non-painful stimuli (allodynia). Neuropathic pain is difficult to treat because of different symptoms and mechanisms involved in its occurrence. Although opioid analgesics can be an effective treatment option in many cases of severe chronic pain, in many cases of neuropathic pain conditions using them alone may not be fully effective. Opioids are usually considered as a second or third line treatment option in neuropathic pain. In many cases an effective treatment cannot be achieved due to poor tolerability of it or side effects. Tapentadol prolonged release, a centrally acting analgesic with 2 mechanisms of action, μ-opioid receptor agonist and noradrenaline reuptake inhibitor, provides strong and reliable analgesia across a range of indications, including nociceptive, neuropathic, and mixed types of chronic pain, and is associated with an improved tolerability profile relative to classic opioid analgesics. The purpose of this article was to demonstrate clinical efficacy of tapentadol PR in association to pregabalin for the treatment of neuropathic pain caused by oxaliplatin chemotherapy.

Abstract

Neuropathic pain is a pain caused by damage or disease affecting the somatosensory nervous system (peripheral or central). There may be various origins of NP, such as infection, trauma, metabolic disorders, chemotherapy, surgery and/or neural compression. Patients usually report a continuous burning pain, which may be accompanied by paroxysms of lancinating or electrical pain — spontaneous or secondary to small stimuli. Pain may occur as response to a painful stimulus (hyperalgesia), or in response to non-painful stimuli (allodynia). Neuropathic pain is difficult to treat because of different symptoms and mechanisms involved in its occurrence. Although opioid analgesics can be an effective treatment option in many cases of severe chronic pain, in many cases of neuropathic pain conditions using them alone may not be fully effective. Opioids are usually considered as a second or third line treatment option in neuropathic pain. In many cases an effective treatment cannot be achieved due to poor tolerability of it or side effects. Tapentadol prolonged release, a centrally acting analgesic with 2 mechanisms of action, μ-opioid receptor agonist and noradrenaline reuptake inhibitor, provides strong and reliable analgesia across a range of indications, including nociceptive, neuropathic, and mixed types of chronic pain, and is associated with an improved tolerability profile relative to classic opioid analgesics. The purpose of this article was to demonstrate clinical efficacy of tapentadol PR in association to pregabalin for the treatment of neuropathic pain caused by oxaliplatin chemotherapy.

Get Citation

Keywords

neuropathic pain, chemotherapy induced neuropathy, opioid analgesics, tapentadol prolonged release

About this article
Title

Neuropathic pain after chemotherapy treated with tapentadol — a case report

Journal

Palliative Medicine in Practice

Issue

Vol 11, No 1 (2017)

Article type

Case report

Pages

36-40

Published online

2017-09-19

Bibliographic record

Medycyna Paliatywna w Praktyce 2017;11(1):36-40.

Keywords

neuropathic pain
chemotherapy induced neuropathy
opioid analgesics
tapentadol prolonged release

Authors

Anna Przeklasa-Muszyńska
Magdalena Kocot-Kępska
Jan Dobrogowski

References (13)
  1. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008; 70(18): 1630–1635.
  2. McDermott AM, Toelle TR, Rowbotham DJ, et al. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain. 2006; 10(2): 127–135.
  3. Szczudlik A, Dobrogowski J, Wordliczek J, et al. Diagnosis and management of neuropathic pain: review of literature and recommendations of the Polish Association for the Study of Pain and the Polish Neurological Society - Part Two. Neurol Neurochir Pol. 2014; 48(6): 423–435.
  4. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015; 14(2): 162–173.
  5. Saif MW, Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag. 2005; 1(4): 249–258.
  6. Velasco R, Bruna J. [Chemotherapy-induced peripheral neuropathy: an unresolved issue]. Neurologia. 2010; 25(2): 116–131.
  7. Dworkin RH, O'Connor AB, Kent J, et al. International Association for the Study of Pain Neuropathic Pain Special Interest Group. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain. 2013; 154(11): 2249–2261.
  8. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013(8): CD006146.
  9. Tzschentke TM, Christoph T, Kögel BY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs. 2014; 28(4): 319–329.
  10. Baron R, Eberhart L, Kern KU, et al. Tapentadol prolonged release for chronic pain: a review of clinical trials and 5 years of routine clinical practice data. Pain Pract. 2017; 17(5): 678–700.
  11. Farmakoterapia bólu. Red. Dobrogowski J, Wordliczek J, Woroń J. Wydawnictwo Medyczne Termedia, Poznań 2014.
  12. Pierce DM, Shipstone E. Pharmacology update: tapentadol for neuropathic pain. Am J Hosp Palliat Care. 2012; 29(8): 663–666.
  13. Afilalo M, Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician. 2013; 16(1): 27–40.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Medycyna Paliatywna w Praktyce dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl